PMID- 37424803
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230718
IS  - 2156-6976 (Print)
IS  - 2156-6976 (Electronic)
IS  - 2156-6976 (Linking)
VI  - 13
IP  - 6
DP  - 2023
TI  - The splicing factor proline and glutamine rich promotes the growth of 
      osteosarcoma via the c-Myc signaling pathway.
PG  - 2488-2503
AB  - Splicing factor proline- and glutamine-rich (SFPQ) regulates transcripts in 
      skeletal muscle metabolism and tumorigenesis. As osteosarcoma (OS) is the most 
      common malignant bone tumor characterized by genome instability, such as MYC 
      amplification, this study aimed to investigate the role and mechanism of SFPQ in 
      OS. Expression of SFPQ in OS cell lines and human OS tissues was detected using 
      quantitative real-time PCR, western blot, and fluorescence in situ hybridization 
      (FISH) analyses. The oncogenic role of SFPQ in OS cells and murine xenograft 
      models and the underlying mechanism of SFPQ on the c-Myc signaling pathway were 
      assessed in vitro and in vivo. Results showed that SFPQ expression was 
      upregulated and correlated with poor prognosis in OS patients. SFPQ 
      overexpression promoted the malignant biological behavior of OS cells, while its 
      knockdown markedly reduced the oncogenic function of OS. Additionally, depletion 
      of SFPQ inhibited OS growth and bone destruction in nude mice. SFPQ 
      overexpression induced malignant biological behaviors, which could be rescued by 
      the depletion of c-Myc. These results suggest an oncogenic role of SFPQ in OS, 
      possibly through the c-Myc signaling pathway.
CI  - AJCR Copyright (c) 2023.
FAU - Mao, Lianghao
AU  - Mao L
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
AD  - Faculty of Medicine, Heidelberg University Heidelberg 69120, Germany.
FAU - Jiang, Pan
AU  - Jiang P
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
AD  - Guizhou Orthopedics Hospital Guiyang 550002, Guizhou, China.
FAU - Lei, Xuan
AU  - Lei X
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
FAU - Zhang, Bing
AU  - Zhang B
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
FAU - Zhong, Xinyu
AU  - Zhong X
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
FAU - Yin, Zhengyu
AU  - Yin Z
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
FAU - Wang, Yongjie
AU  - Wang Y
AD  - Department of Orthopedic Surgery, Shanghai Tenth People's Hospital Affiliated to 
      Tongji University Shanghai 200072, China.
FAU - Li, Dapeng
AU  - Li D
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
FAU - Zhang, Yiming
AU  - Zhang Y
AD  - Affiliated Hospital of Jiangsu University Zhenjiang 212001, Jiangsu, China.
FAU - Zheng, Qiping
AU  - Zheng Q
AD  - Department of Laboratory Science, School of Medicine, Jiangsu University 
      Zhenjiang 212013, Jiangsu, China.
AD  - Shenzhen Walgenron Bio-Pharm Co., Ltd. Shenzhen 518118, Guangdong, China.
LA  - eng
PT  - Journal Article
DEP - 20230615
PL  - United States
TA  - Am J Cancer Res
JT  - American journal of cancer research
JID - 101549944
PMC - PMC10326564
OTO - NOTNLM
OT  - Splicing factor proline- and glutamine-rich (SFPQ)
OT  - c-Myc signaling
OT  - osteosarcoma
OT  - progression
COIS- None.
EDAT- 2023/07/10 06:42
MHDA- 2023/07/10 06:43
PMCR- 2023/06/15
CRDT- 2023/07/10 04:48
PHST- 2023/03/16 00:00 [received]
PHST- 2023/05/22 00:00 [accepted]
PHST- 2023/07/10 06:43 [medline]
PHST- 2023/07/10 06:42 [pubmed]
PHST- 2023/07/10 04:48 [entrez]
PHST- 2023/06/15 00:00 [pmc-release]
PST - epublish
SO  - Am J Cancer Res. 2023 Jun 15;13(6):2488-2503. eCollection 2023.